依达拉奉联合尤瑞克林治疗进展性脑梗死的疗效观察

目的观察依达拉奉联合尤瑞克林治疗进展性脑梗死的临床疗效。方法将近年来该院收治的90例急性进展性脑梗死患者随机分为治疗组与对照组各45例，两组患者除常规给予拜阿司匹林抗凝、阿托伐他汀降脂、疏血通改善循环等治疗外，对照组另给予依达拉奉治疗，治疗组另给予依达拉奉联合尤瑞克林治疗，观察比较两组患者治疗前后神经功能损伤情况、血液流变学改变及临床疗效。结果治疗组临床疗效优于对照组（ P＜0.01）。两组神经功能缺损评分和血液流变学各项指标治疗后均有下降（ P＜0.05或＜0.01），且治疗组的下降幅度大于对照组（P＜0.01）。结论依达拉奉联合尤瑞克林对进展性脑梗死具有很好的治疗效果。

Clinical efficacy of edarovone combined with kailldinogenase in treating patients with progressive cerebral infarction

Objective To explore the clinical efficacy of edarovone combined with kailldinogenase in treating patients with progressive cerebral infarction .Methods Ninety patients with acute progressive cerebral infarction trea-ted in the people′s hospital of Anxi county recently were randomly divided into treatment group （45 cases） and control group（45 cases）.All the patients received the routine treatment such as aspirin for anticoagulation ,atorvastatin for reducing lipid,shuxuetong for improving circulation ,and so on.On the basis of above treatment ,the control group was treated with edarovone ,while the treatment group was treated with edarovone combined with kailldinogenase .The neu-rological injury ,blood rheology changes and clinical efficacy before and after treatment were observed and compared . Results The clinical efficacy of treatment group was better than that of the control group （ P＆lt;0.01 ） .The neurologic deficit scale ,hemorheology indexes after treatment declined significantly in two groups （ P＆lt;0.05 or P＆lt;0.01 ） , but the declined extent in the treatment group was greater than that in the control group （ P＆lt;0.01 ） .Conclusion Edaro-vone combined with kailldinogenase shows good clinical efficacy in treating progressive cerebral infaretion .